

NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 11/15/2022)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease	Recurrent Disease
<p>Rhabdomyosarcoma (RMS)</p> <p>ARST2031 (High risk)</p>	<p>Acute Lymphoblastic Leukemia (ALL)</p> <p>AALL1821</p>
<p>Adenocarcinoma of the colon</p> <p>A021502 (ATOMIC)</p>	<p>Classical Hodgkin Lymphoma</p> <p>E4412</p>
<p>Classical Hodgkin Lymphoma</p> <p>S1826</p>	<p>Osteosarcoma (Pulmonary Mets)</p> <p>AOST2031</p>
<p>TFE/Translocation Renal Cell Carcinoma (tRCC)</p> <p>AREN1721</p>	<p>Germ Cell Tumors</p> <p>AGCT1531 AGCT1532</p>
<p>Osteosarcoma (Pulmonary Mets)</p> <p>AOST2031</p>	<p>Acute Lymphoblastic Leukemia (ALL)</p> <p>A041501</p>
	<p>Nongerminomatous germ cell tumor of the CNS</p> <p>ACNS2021</p>
	<p>Mediastinal (thymic) large B-cell lymphoma</p> <p>ANHL1931</p>

Legend by Disease Types

Green = Rhabdomyosarcoma (RMS)	Yellow = Germ Cell Tumors	Orange = Hodgkin Lymphoma	Blue = ALL	Purple = tRCC	Lime Green = Osteosarcoma	Light Purple = CNS NGGCT	Gray = PMBCL	Light Blue = Adenocarcinoma of the colon
--------------------------------	---------------------------	---------------------------	------------	---------------	---------------------------	--------------------------	--------------	--

Cross-disease trials

EAY131 (MATCH)

S1609 (DART)*

*: COG not participating

NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 11/15/2022)

Protocol Number	Phase	Protocol Title
A021502	III	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
A041501	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
AALL1821	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >= 1 to < 31 Years Old with First Relapse
ACNS2021	II	A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
AGCT1531	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
ANHL1931	III	A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AREN1721	II	A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
ARST2031	III	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
E4412	I/II	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
S1826	III	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
EAY131	II	Molecular Analysis for Therapy Choice (MATCH)
S1609*	II	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

*: COG not participating